145 related articles for article (PubMed ID: 38335471)
1. Prognostic Role of Ventricular Size and Its Dynamics in Patients With Leptomeningeal Metastasis From Solid Tumors.
Le Rhun E; Devos P; Seystahl K; Jongen JLM; Gramatzki D; Roth P; Van Den Bent MJ; Regli L; Brandsma D; Weller M
Neurology; 2024 Mar; 102(5):e207959. PubMed ID: 38335471
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers.
Nakagawa K; Takano K; Nishino K; Ohe S; Nakayama T; Arita H
J Neurooncol; 2024 May; 167(3):397-406. PubMed ID: 38430420
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases.
Jung TY; Chung WK; Oh IJ
Clin Neurol Neurosurg; 2014 Apr; 119():80-3. PubMed ID: 24635931
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors.
Waki F; Ando M; Takashima A; Yonemori K; Nokihara H; Miyake M; Tateishi U; Tsuta K; Shimada Y; Fujiwara Y; Tamura T
J Neurooncol; 2009 Jun; 93(2):205-12. PubMed ID: 19043775
[TBL] [Abstract][Full Text] [Related]
5. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H
Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171
[TBL] [Abstract][Full Text] [Related]
6. The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute.
Yan W; Jing W; An N; Tian Y; Guo D; Kong L; Zhu H; Yu J
Cancer Med; 2019 Jun; 8(6):2769-2776. PubMed ID: 30993909
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features and prognostic factors in patients with leptomeningeal metastases].
Li N; Yang BY; Li JL; Zhu JQ; Zou BH; Wang YF; Yu L; Yao XY
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):867-70. PubMed ID: 24447488
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of Clinicopathological Feature and Prognosis for
Leptomeningeal Metastasis in Non-small Cell Lung Cancer].
Zhu M; Ren Y; Liu Y; Ban C; Gu H; Wang Z; Zhang Y
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):533-8. PubMed ID: 27561804
[TBL] [Abstract][Full Text] [Related]
9. Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM).
Niwińska A; Pogoda K; Michalski W; Kunkiel M; Jagiełło-Gruszfeld A
J Neurooncol; 2018 May; 138(1):191-198. PubMed ID: 29435818
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of molecular characteristics of cerebrospinal fluid for non-small cell lung cancer patients with leptomeningeal metastasis.
Li N; Liu Y; Duan J; Yang B; Bai H; Sun R; Yu L; Wang J
Thorac Cancer; 2019 Aug; 10(8):1673-1682. PubMed ID: 31368671
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
12. Leptomeningeal metastasis: Clinical experience of 519 cases.
Hyun JW; Jeong IH; Joung A; Cho HJ; Kim SH; Kim HJ
Eur J Cancer; 2016 Mar; 56():107-114. PubMed ID: 26841095
[TBL] [Abstract][Full Text] [Related]
13. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
[TBL] [Abstract][Full Text] [Related]
14. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B
J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
Zhou T; Zhu S; Xiong Q; Gan J; Wei J; Cai J; Liu A
BMC Cancer; 2023 Apr; 23(1):333. PubMed ID: 37041504
[TBL] [Abstract][Full Text] [Related]
16. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
Wu YL; Zhao Q; Deng L; Zhang Y; Zhou XJ; Li YY; Yu M; Zhou L; Zou BW; Lu Y; Liu YM
Lung Cancer; 2019 Jan; 127():1-5. PubMed ID: 30642536
[TBL] [Abstract][Full Text] [Related]
17. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
Riess JW; Nagpal S; Iv M; Zeineh M; Gubens MA; Ramchandran K; Neal JW; Wakelee HA
Clin Lung Cancer; 2014 May; 15(3):202-6. PubMed ID: 24524822
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.
Lu ZQ; Cai J; Wang X; Wei JP; Zeng ZM; Huang L; Liu AW
Thorac Cancer; 2021 Jan; 12(2):172-180. PubMed ID: 33205587
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis.
Oechsle K; Lange-Brock V; Kruell A; Bokemeyer C; de Wit M
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1729-35. PubMed ID: 20204406
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
